DarolutamideApalutamideenzalutamidedarolutamidaARASENSandrogen deprivation therapy
…metastatic hormone-sensitive prostate cancer (mHSPC) (ARASENS). Darolutamide was commercialised in 2020.Aim and Objectives To evaluate the t…
5articles mentioning drugs
22drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Darolutamide ×
Darolutamide
This drug is selected. Its supporting articles are shown below.
Articles mentioning Darolutamide
5 articles · page 1 of 1darolutamideProstate cancer (PCa)Amsterdam UMCcastration-resistant PCa
…egulation following treatment with AR targeting agents, such as darolutamide, particularly in patients with castration-resistant PCa. This t…
docetaxelabirateronedarolutamideARASENSenzalutamideapalutamidePEACE-1mHSPCde novo mHSPCmetastatic hormone-sensitive prostate cancer (mHSPC)+4 more
…eceived abiraterone, 31% apalutamide, 26% enzalutamide, and 11% docetaxel. Median PFS and OS were 32 and 50 months, respectively, in the …
abirateroneolaparibapalutamidedarolutamideenzalutamideprostate cancerBasic Clin Pharmacol Toxicol
…Results Of 88 patients (mean age 76.9 ± 8.2 years), 70 received abiraterone, 8 apalutamide, six enzalutamide, three darolutamide, and one o…
darolutamidemetastatic hormone sensitive prostate cancerandrogen deprivation therapyNational Institute for Health and Care ExcellenceNICEchemotherapyADT
…Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen deprivation therapy (ADT) as a tre…